Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.
Profitability
This table compares Taysha Gene Therapies and Cytokinetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Taysha Gene Therapies | N/A | -56.19% | -41.84% |
| Cytokinetics | -1,321.12% | N/A | -51.01% |
Valuation and Earnings
This table compares Taysha Gene Therapies and Cytokinetics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Taysha Gene Therapies | $9.77 million | 167.42 | -$109.00 million | ($0.42) | -11.95 |
| Cytokinetics | $88.04 million | 104.26 | -$784.96 million | ($7.22) | -10.22 |
Taysha Gene Therapies has higher earnings, but lower revenue than Cytokinetics. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and recommmendations for Taysha Gene Therapies and Cytokinetics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Taysha Gene Therapies | 1 | 0 | 11 | 2 | 3.00 |
| Cytokinetics | 1 | 1 | 18 | 0 | 2.85 |
Taysha Gene Therapies presently has a consensus price target of $12.77, indicating a potential upside of 154.37%. Cytokinetics has a consensus price target of $103.37, indicating a potential upside of 40.12%. Given Taysha Gene Therapies’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Taysha Gene Therapies is more favorable than Cytokinetics.
Risk and Volatility
Taysha Gene Therapies has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500.
Insider and Institutional Ownership
77.7% of Taysha Gene Therapies shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Taysha Gene Therapies beats Cytokinetics on 11 of the 15 factors compared between the two stocks.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
About Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo-1200x675.jpg){kind=logo}
